Compare HP Inc (HPQ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Novo Nordisk A/S — how do they compare? HP Inc trades at $30.2 (market cap $29.25B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 5.7× HP Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Novo Nordisk A/S for 116 Days on average.
| HPQ | NVO | |
|---|---|---|
Market Cap | $29.25B | $165.31B |
Volume | 10,025,806 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $35.48 | $63.98 |
52-Week Low | $18.20 | $35.29 |
Typical Hold Time | 69 Days | 116 Days |
Enterprise Value | $35.42B | $179.56B |
Dividend Yield | 3.7% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.44, up 0.62% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is projected to grow to $59.2B in 2026, though net margins are compressing. Recent news highlights HP's new AI-ready PCs but also a cautious outlook for 2027 PC sales.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38, but declining PC demand poses a headwind. Analyst consensus is cautious with a hold-heavy rating, though the stock offers a 3.82% dividend yield. Key risks include execution in a competitive hardware market and macroeconomic sensitivity.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
